Browsing Centro Académico de Salud (CAS) by Subject "Immunotherapy"
Now showing items 1-4 of 4
-
Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina
(Elsevier, 2020-09)Abstract Background: Nivolumab was the first anti-programmed cell death 1 drug approved in Argentina for non-small-cell lung cancer treatment in the second-line setting. Materials and methods: The present study was a ... -
Immunology of Bee Venom
(Humana Press, 2017-03-01)Introduction Previous studies show contradictory results related to the vascular effects of coffee; they suggest that caffeine increases arterial stiffness and negatively impacts vascular health, the aim of this study is ... -
Immunotherapy for Hepatocellular Carcinoma: Is Latin America Ready for Primetime?
(AASLD, 2020-09)Potential conflict of interest: Nothing to report. Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer‐related death worldwide, and its mortality is increasing steadily.1 HCC incidence has grown in the ... -
Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting
(Springer, 2021-06)Abstract Background: Immune-checkpoint inhibitors (ICIs) are standard treatments for metastatic non-small cell lung cancer (NSCLC). Patients with poor performance status (PS) are underrepresented in clinical trials. We ...